A provider briefing on the Octreotide shortage in 2026: timeline, prescribing implications, availability, cost, and clinical tools.
Octreotide supply disruptions have created real challenges for clinicians managing patients with acromegaly, carcinoid syndrome, and neuroendocrine tumors. As a provider, you need current information to make timely treatment decisions and help your patients maintain continuity of care. This article provides a comprehensive overview of the shortage, its clinical implications, and the tools available to help.
Octreotide supply issues have followed a multi-year trajectory:
The shortage requires clinicians to consider several prescribing strategies:
When the LAR formulation is unavailable, bridging with immediate-release subcutaneous Octreotide is a well-established approach. Patients previously stable on Octreotide LAR 20-30 mg monthly can be transitioned to subcutaneous Octreotide 100-200 mcg two to three times daily. This requires patient education on self-injection technique and may temporarily affect quality of life due to the increased injection burden.
Teva's generic Octreotide LAR is bioequivalent to Sandostatin LAR Depot. For patients currently on the brand, generic substitution is appropriate when available and may improve access through different distribution channels. Note that pharmacy-level substitution policies vary by state and payer.
When Octreotide is unavailable in any formulation, the primary therapeutic alternative is Lanreotide (Somatuline Depot). Lanreotide is manufactured by Ipsen and has an independent supply chain, making it a practical backup when Octreotide supply is constrained. Clinical evidence supports comparable efficacy in both acromegaly and GEP-NETs.
For acromegaly patients inadequately controlled on first-generation somatostatin analogs, Pasireotide LAR (Signifor LAR) remains an option, though the higher incidence of hyperglycemia requires additional monitoring. Pegvisomant (Somavert) provides an alternative mechanism of action for acromegaly via growth hormone receptor blockade.
For carcinoid syndrome, Telotristat Ethyl (Xermelo) can be added to manage diarrhea when SSA therapy is insufficient or disrupted, though it is not a standalone replacement for Octreotide's broader antisecretory effects.
The table below summarizes the current availability status of Octreotide formulations:
Immediate-Release Injection (SC/IV):
LAR Injection (IM):
Other Formulations:
For real-time availability information, Medfinder for Providers offers pharmacy-level stock data to help locate supply for your patients.
Octreotide pricing varies substantially by formulation and manufacturer:
Most insurance plans cover Octreotide but require prior authorization. Common payer requirements include:
When switching between Octreotide products or to alternatives due to the shortage, expedited prior authorization may be necessary. Document the clinical rationale for the switch — most payers will accommodate shortage-related changes with appropriate documentation.
The Octreotide supply landscape is gradually improving. Teva's generic LAR production is expected to stabilize through 2026, which should reduce dependence on the single-source brand product. The growing adoption of Mycapssa for appropriate acromegaly patients may also reduce demand on injectable supply.
However, the fundamental manufacturing complexity of the LAR microsphere formulation means that supply vulnerability will persist until additional manufacturers enter the market. Clinicians should continue to maintain contingency plans, including familiarity with alternative agents and bridging protocols.
Managing patients through drug shortages requires proactive planning, flexible prescribing, and reliable information. Tools like Medfinder for Providers can help you locate Octreotide supply quickly, and staying informed about the evolving availability picture enables you to make the best decisions for your patients.
For additional clinical resources, see our companion articles: How to Help Your Patients Find Octreotide in Stock and How to Help Patients Save Money on Octreotide.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
